BioSpace News Archive

Drug Development

AC Immune Hosts KOL Event and Reports Initial Interim Clinical Data for ACI-24 Vaccine to Treat Alzheimer’s Disease-like Symptoms in Subjects with Down Syndrome

Anti-Abeta vaccine demonstrates strong safety and preliminary immunogenicity results in subjects with Down syndrome

July 11, 2019
·
9 min read
Policy

Reckitt Benckiser Settles Indivior Opioid Investigation for $1.4 Billion

Reckitt Benckiser spun Indivior off into a standalone company in 2014. Earlier this year the Department of Justice charged Indivior for its role in the opioid crisis.

July 11, 2019
·
2 min read
·
Alex Keown
Research Roundup: New Test for Autism and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

July 11, 2019
·
4 min read
·
Mark Terry
New Insights into the Vagus Nerve Could Change the Way Diabetes is Treated

A team of researchers finally learned how the vagus nerve transmits its signals, which could have implications in revealing a new way to measure blood glucose levels in people.

July 11, 2019
·
2 min read
·
Alex Keown
Business

BioSpace Movers and Shakers, July 12

Biotech and pharma companies strengthen their leadership teams with new appointments.

July 11, 2019
·
5 min read
·
Alex Keown
Deals

Heidelberg Pharma reports on first half-year

Heidelberg Pharma AG published its financial report on the first six months of 2019

July 11, 2019
·
8 min read
Business

BioArctic Interim Report January – June 2019

BioArctic received MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s disease

July 11, 2019
·
7 min read
Novotech CRO partners Skin Research Institute of Singapore (SRIS) for Skin Disorder Research

Novotech, the award-winning Asia-Pacific CRO, has further strengthened its presence in the region through a Partnership with the Skin Research Institute of Singapore.

July 11, 2019
·
1 min read
Drug Development

Prescient Therapeutics Initiates Phase 1b Clinical Trial for First-in Class Anti-Cancer Drug PTX-100 in Patients with Multiple Cancers

Prescient Therapeutics Limited, a clinical stage oncology company, announced the start of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in Australia.

July 11, 2019
·
6 min read
Biotech Beach

Epigenomics AG Receives MedTech Outlook‘s 2019 Top 10 In-Vitro Diagnostics Award

Company recognized for its leadership in advancing blood-based tests to diagnose cancer

July 11, 2019
·
3 min read